Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. (Nasdaq: ERAS) is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Their mission, embodied in their name, is to 'erase cancer'. The company's innovative approach aims to not just treat but potentially cure cancer by targeting and shutting down the RAS/MAPK pathway, which plays a crucial role in many types of cancer.
Erasca’s robust clinical pipeline includes promising drug candidates such as Naporafenib, a pan-RAF inhibitor with first-in-class potential targeting NRASm melanoma and RAS Q61X tissue agnostic solid tumors. The company's other notable candidates include ERAS-007, a highly selective oral ERK1/2 inhibitor, and ERAS-601, an oral SHP2 inhibitor, which target different nodes of the RAS/MAPK pathway. These efforts are supported by recent collaborations with industry giants like Novartis, who are providing crucial compounds like trametinib (MEKINIST®) for combination trials.
On the financial front, Erasca is well-funded with significant investments from both new and existing investors, having recently raised approximately $45 million in a private placement expected to close in April 2024. As of December 2023, the company reported $322 million in cash, cash equivalents, and marketable securities, ensuring a solid runway into the second half of 2026.
Among their latest achievements, Erasca has received FDA Fast Track Designation (FTD) for Naporafenib in combination with trametinib for advanced NRASm melanoma. This designation facilitates accelerated development and review processes, reflecting the potential of their therapies to address unmet medical needs.
The company’s pivotal Phase 3 SEACRAFT-2 trial for Naporafenib in post-immunotherapy settings for NRASm melanoma is slated to begin in the first half of 2024. Additionally, Erasca has announced exciting new partnerships and pipeline enhancements, including in-licensing two preclinical RAS programs, ERAS-0015 and ERAS-4001, to further solidify their leadership in the precision oncology space.
For more up-to-date information on Erasca, Inc., including their latest financial results and key upcoming milestones, visit their official website or recent press releases.
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company focused on therapies for RAS/MAPK pathway-driven cancers, will present at the 2022 Jefferies Healthcare Conference on June 10, 2022, at 8:00 AM ET in New York. CEO Jonathan E. Lim and CFO David M. Chacko will represent the company and participate in one-on-one investor meetings. A live webcast and an archived replay of the presentation will be available online, continuing until September 10, 2022. Erasca’s mission is to erase cancer through innovative therapies targeting the RAS/MAPK pathway.
Erasca, Inc. (NASDAQ: ERAS) announced a Phase 1b clinical trial for ERAS-007, an ERK1/2 inhibitor, in combination with a KRAS G12C inhibitor, targeting KRAS G12C-driven non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). This trial aims to address RAS/MAPK resistance issues linked to KRAS G12C inhibitors. Preliminary data suggests ERAS-007 may effectively counteract drug resistance mechanisms. The trial will be led by renowned investigators, with additional research planned to assess the safety and efficacy of this combination.
Erasca, Inc. (Nasdaq: ERAS) announced key appointments aimed at advancing its clinical development efforts in precision oncology. Shannon Morris, M.D., Ph.D., joins as Senior Vice President of Clinical Development, bringing over 20 years of experience in oncology. Amy Grekowicz Parker is appointed Vice President of Clinical Operations, with a strong background in managing clinical studies. John Lo, Ph.D., takes on the role of Senior Commercial Advisor, leveraging his extensive expertise in biopharmaceutical commercialization. These strategic appointments are expected to bolster Erasca's pipeline focused on RAS/MAPK pathway-driven cancers.
Erasca, Inc. (Nasdaq: ERAS) reported its Q1 2022 financials, highlighting a cash position of $421.8 million expected to support operations into H2 2024. The company continues to progress its pipeline, with initial Phase 1b data for ERAS-007 and ERAS-601 expected in H2 2022, alongside an IND filing for ERAS-3490. R&D expenses rose significantly to $27.4 million, impacting net loss, which increased to $36.5 million or $(0.31) per share compared to last year. Encouraging preclinical and clinical developments were presented at the AACR Annual Meeting.
Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company, announced its participation in the Bank of America Securities 2022 Healthcare Conference. CEO Jonathan E. Lim, M.D., and CFO David M. Chacko, M.D., will engage in a virtual fireside chat on May 10, 2022, at 1:20 p.m. PT. They will also hold one-on-one investor meetings. A live webcast will be available on the Bank of America website, with an archived replay accessible until August 10, 2022. Erasca focuses on developing therapies for RAS/MAPK pathway-driven cancers, aiming to erase cancer.
Erasca has appointed Jean Liu, currently chief legal officer at Seagen, to its board of directors and audit committee. With over 20 years of experience in the biopharmaceutical sector, Liu has been instrumental in Seagen’s growth into a leading oncology company. Erasca aims to enhance its leadership team amid advancements in their RAS/MAPK pathway-focused pipeline, which targets various cancers. Liu’s expertise will support Erasca's mission to develop innovative therapies and address unmet needs in cancer treatment.
Erasca, Inc. (Nasdaq: ERAS) presented preclinical data from six poster presentations at the AACR Annual Meeting, showcasing three key candidates: ERAS-007, a selective ERK1/2 inhibitor; ERAS-601, a potent SHP2 inhibitor; and ERAS-3490, a CNS-penetrant KRAS G12C inhibitor. ERAS-007 shows promising activity in RAS/MAPK pathway-driven colorectal cancer, while ERAS-601 demonstrates anti-tumor activity in various models. ERAS-3490 targets CNS involvement in KRAS G12C mutant lung cancer. Initial clinical data for these candidates is expected in the near future, highlighting Erasca's commitment to RAS/MAPK-driven cancer therapies.
Erasca, Inc. (Nasdaq: ERAS) will host a virtual investor event on April 12, 2022, at 4:30 PM ET to discuss therapeutic opportunities in RAS/MAPK pathway-driven cancers, particularly gastrointestinal cancers. Key opinion leader Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center will present insights on unmet medical needs and Erasca's approach. The company will detail its pipeline and clinical development strategy targeting various cancers, including non-small cell lung cancer and hematologic malignancies. Registration and webcast details are available on the Erasca website.
Erasca reported Q4 2021 financial results, achieving clinical milestones ahead of schedule. The company has a strong cash position of $459 million as of December 31, 2021, up from $118.7 million a year prior. Major trial updates include ERAS-007, ERAS-601, and ERAS-801, with initial Phase 1b data expected in H2 2022. R&D expenses rose to $24.1 million for Q4 2021, reflecting increased clinical trial activity. The net loss improved to $30.5 million for Q4 2021 from $61.9 million in Q4 2020, indicating progress.
Erasca has announced a collaboration with Eli Lilly to evaluate ERAS-007, an ERK1/2 inhibitor, in a Phase 1b/2 HERKULES-3 trial for BRAF V600E-mutant metastatic colorectal cancer (mCRC). The study will explore the combination of ERAS-007 with encorafenib and cetuximab, aiming to overcome resistance mechanisms linked to MAPK pathway reactivation. This approach is bolstered by preclinical data suggesting that ERAS-007 could enhance treatment efficacy. Approximately 180,000 patients with BRAF V600E mutations are affected globally, highlighting the potential market impact.
FAQ
What is the current stock price of Erasca (ERAS)?
What is the market cap of Erasca (ERAS)?
What is Erasca, Inc.'s primary focus?
What are the key drugs in Erasca’s pipeline?
What recent achievements has Erasca reported?
How is Erasca funded?
What partnerships has Erasca entered into?
What is the SEACRAFT-2 trial?
What does FDA Fast Track Designation mean for Erasca?
What financial milestones has Erasca achieved recently?
What is the significance of Erasca's mission statement?
How does Erasca's technology target cancer?
